Phenylketonuria (PKU) Clinical Trials and Treatments

Phenylketonuria (PKU) is an inherited metabolic disorder caused by a deficiency of the enzyme phenylalanine hydroxylase, which normally converts the amino acid phenylalanine into tyrosine. Without this enzyme, phenylalanine accumulates to toxic levels in the blood and cerebrospinal fluid, causing intellectual disability, behavioral problems, and neurological complications if left untreated. Fortunately, PKU is one of the first conditions routinely screened for in newborns across the U.S.

The most common symptoms of Phenylketonuria include Light-colored skin and hair, Musty or mousy odor in sweat or urine, Intellectual disability if untreated, Behavioral problems or hyperactivity, Eczema or other skin conditions, among others. Phenylketonuria affects approximately 1 in 10,000 to 15,000 newborns in the U.S.. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Phenylketonuria from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Gene therapies and enzyme replacement approaches are transforming PKU treatment beyond dietary management. Several medicines are already FDA-approved to add to the PKU diet: sapropterin (Kuvan, approved in 2007 and now also sold as generics) and sepiapterin (Sephience, approved in July 2025) are taken by mouth by people whose blood phenylalanine responds, and pegvaliase (Palynziq, approved in 2018) is an injected enzyme for people 12 and older whose blood phenylalanine stays above 600 µmol/L on existing management.

Yes. As of September 2026, Trial Friend lists 1 FDA-approved drug used to treat Phenylketonuria: Sephience (sepiapterin), first approved in 2025.

Each has its own page with what the label covers, side effects and how it is given, and the Treatments section of this page adds any further approved drugs found in FDA labeling data.

Phenylketonuria is caused by variants in the PAH gene. Nearly all cases are biallelic PAH variants; residual enzyme activity determines whether it is classic PKU or milder hyperphenylalaninemia.

It is inherited in an autosomal recessive pattern: both parents are usually unaffected carriers, and each pregnancy has a 1 in 4 chance of an affected child. The condition affects approximately 1 in 10,000 to 15,000 newborns in the U.S. Genetic testing confirms the diagnosis.

Yes. Genetic testing for Phenylketonuria looks at the PAH gene. Nearly all cases are biallelic PAH variants; residual enzyme activity determines whether it is classic PKU or milder hyperphenylalaninemia.

It is inherited in an autosomal recessive pattern: both parents are usually unaffected carriers, and each pregnancy has a 1 in 4 chance of an affected child.

A confirmed variant establishes the diagnosis and is often required to enroll in gene-specific trials. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Phenylketonuria clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Phenylketonuria clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.